Health Canada recently released for consultation the Draft Guidance Document – Administrative Processing of Submissions and Applications Involving Human or Disinfectant Drugs. Stakeholders may provide comments on the draft guidance document by email to Policy_Bureau_Enquiries@hc-sc.gc.ca. The consultation period is open until April 18, 2017.
The draft guidance document outlines the conditions and procedures by which Health Canada administratively processes a change in manufacturer name and/or product name as a result of business circumstances (such as licensing arrangements or mergers/buyouts), when there are no deviations to the product.
One finalized, this guidance document will replace Health Canada's policy Change in Manufacturer's / Product Name Policy, which currently governs the administrative processing of drug submissions and applications.
The draft guidance document addresses current policy gaps that have been identified and provides clarity to industry on the requirements under this administrative pathway.
Generally, the types of applications that will be eligible for administrative processing include:
- manufacturer name change
- product name change
- product ownership change (i.e., change in DIN holder)
- merger or buyout
- additional product name
- licensing agreement between two manufacturers (this policy does not govern secondary licensing agreements between licensees and third parties)
- revised/updated product monograph
This draft guidance document provides additional information about the roles and responsibilities of manufacturers, licensors and licensees, as well as the types documentation and attestations required upon submission.
The draft also sets out some expectations on labelling considerations, including a six-month phased-in period to replace original product labels with new product labels for manufacturers transitioning their products under new business arrangements.
About Norton Rose Fulbright Canada LLP
Norton Rose Fulbright is a global law firm. We provide the world's preeminent corporations and financial institutions with a full business law service. We have 3800 lawyers and other legal staff based in more than 50 cities across Europe, the United States, Canada, Latin America, Asia, Australia, Africa, the Middle East and Central Asia.
Recognized for our industry focus, we are strong across all the key industry sectors: financial institutions; energy; infrastructure, mining and commodities; transport; technology and innovation; and life sciences and healthcare.
Wherever we are, we operate in accordance with our global business principles of quality, unity and integrity. We aim to provide the highest possible standard of legal service in each of our offices and to maintain that level of quality at every point of contact.
For more information about Norton Rose Fulbright, see nortonrosefulbright.com/legal-notices.
Law around the world
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.